PRECLINICAL CRO SERVICES FOR ONCOLOGY
a new approach to anticancer therapeutics development
At Certis, we offer a full suite of drug development services that are available as stand-alone services or as part of an end-to-end preclinical program. Our experienced PhD scientists, histology experts and bioinformaticians serve as an extension of your preclinical team, operating under precise and exacting scientific standards. We offer a collaborative and consultative approach, from study design through execution.
Unlike general contract research organizations (CROs), high-touch, high-tech and high-quality oncology intelligence is all we do.
Discover True Partnership
Ask about our preclinical CRO services for drug development.
Custom Model Build
Rapidly Growing Tumor Bank | O-PDX | CDX |
In Vitro/Ex Vivo, In Vivo pharmacology | PK/PD Studies
Certis combines deep expertise in orthotopic engraftment techniques with patient-consented, highly characterized, low-passage tumors from our tumor bank — many pretreated with current standard of care.
Our custom pharmacology services also support rapid, early screening studies with proprietary cell lines derived from our tissue or yours, and a seamless translation from in vitro and ex vivo to in vivo studies. Whether you seek to evaluate drug efficacy, study mechanism of action, identify potential adverse effects, or simply gather PK/PD modeling data, Certis offers the scientific, imaging and analytical horsepower to deliver actionable results.
Request Tumor Bank Access
Bioassay Development
Flow Cytometry | ELISA | ECL | HTRF | IHC
You can rely on a versatile suite of tailored bioassay services to provide you with the detailed drug efficacy data and full endpoint analyses you need. From design and optimization to plate layouts and control, our scientific expertise ensures data integrity and efficiency.
Advanced Imaging Technologies
MRI Tumor Volume Measurement | BLI & Fluorescence Techniques | Targeted Radiation Therapy
Visualize cancer progression and anticancer drug response with speed, flexibility and precision with the latest high-resolution imaging technologies. We can interrogate preclinical issues from different angles — whether it is measuring multiple metastases in the murine liver using magnetic resonance imaging (MRI) or studying tumor response quantitatively and repeatedly in real time through bioluminescence imaging (BLI) and fluorescence techniques.
Spectral Flow Cytometry
3 lasers | 38 detectors | 24 marker panels |
1 preclinical partner
Evaluate drug response with in-house flow cytometry expertise and custom panel design and validation. Leverage the power of flow cytometry, an essential tool in immuno-oncology, to evaluate cell populations, activation, function, biomarkers, viability, apoptosis and cell cycle analysis.
Bioinformatics
CertisAI™ | Target Identification & Tractability | Drug Repositioning |
Biomarkers | In Silico Analyses | CNV Analysis
Our in-house team of PhD-level data scientists harness statistical power— transforming volumes of predictive data points into actionable insights to help identify the best models for your program and support decision-making. Unlike common single-biomarker strategies often employed in precision medicine, CertisAI™ uses multivariate machine learning algorithms to capture the nuance of biomarker interactions and bring greater accuracy to predictions of drug efficacy.